Products for Research Use Only
RegisterLogin

Mivavotinib

CAT: 0804-HY-100867Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-100867Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
TAK-659 is a highly potent, selective, reversible and orally available dual inhibitor of spleen tyrosine kinase (SYK) and fms related tyrosine kinase 3 (FLT3), with an IC50 of 3.2 nM and 4.6 nM for SYK and FLT3, respectively. TAK-659 induces cell death in tumor cells but not in nontumor cells, and with potential for the treatment of chronic lymphocytic leukemia (CLL) [1][2][3][4].
CAS Number
1312691-33-0
Product Name Alternative
TAK-659; CB-659
UNSPSC
12352005
Target
FLT3; Syk
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/mivavotinib.html
Solubility
10 mM in DMSO
Smiles
FC1=C(N[C@@H]2CCCC[C@@H]2N)N=C(C3=CN(C)N=C3)C4=C1CNC4=O
Molecular Formula
C17H21FN6O
Molecular Weight
344.39
References & Citations
[1]Lam B, et al. Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK) . Bioorg Med Chem Lett. 2016 Dec 15;26 (24) :5947-5950.|[2]Purroy N, et al. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells. Oncotarget. 2017 Jan 3;8 (1) :742-756.|[3]Jie Yu, et al. Anti-tumor activity of TAK-659, a dual inhibitor of SYK and FLT-3 kinases, in AML models. Journal of Clinical Oncology 34, no. 15_suppl.|[4]Cen O, et al. Spleen Tyrosine Kinase Inhibitor TAK-659 Prevents Splenomegaly and Tumor Development in a Murine Model of Epstein-Barr Virus-Associated Lymphoma. mSphere. 2018 Aug 22;3 (4) .
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 2

Alternative Products

CatalogName
MCC69133Mivavotinib

Popular Products